Barclays
CRSP icon

Barclays’s CRISPR Therapeutics CRSP Stock Holding History

Barclays’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,000
Closed -$4.98M – 5112
2025
Q4 		$4.98M Sell
95,000
-50,500
-35% -$3.02M ﹤0.01% 2221
2025
Q3 		$9.43M Buy
145,500
+82,500
+131% +$4.74M ﹤0.01% 1703
2025
Q2 		$3.06M Buy
+63,000
New +$2.44M ﹤0.01% 2522
2024
Q4 		– Sell
-30,000
Closed -$1.41M – 5308
2024
Q3 		$1.41M Buy
+30,000
New +$1.52M ﹤0.01% 3128
2024
Q2 		– Sell
-40,700
Closed -$2.77M – 4947
2024
Q1 		$2.77M Sell
40,700
-111,300
-73% -$7.97M ﹤0.01% 2299
2023
Q4 		$9.52M Buy
+152,000
New +$8.4M ﹤0.01% 1551
2023
Q2 		– Sell
-100,000
Closed -$4.52M – 4638
2023
Q1 		$4.52M Buy
100,000
+33,400
+50% +$1.62M ﹤0.01% 1613
2022
Q4 		$2.71M Buy
+66,600
New +$3.53M ﹤0.01% 2038
2021
Q1 		– Sell
-2,500
Closed -$383K – 4768
2020
Q4 		$383K Buy
+2,500
New +$295K ﹤0.01% 3402
2018
Q3 		– Sell
-59,500
Closed -$3.5M – 7157
2018
Q2 		$3.5M Buy
59,500
+37,300
+168% +$2.12M ﹤0.01% 2039
2018
Q1 		$1.01M Buy
+22,200
New +$916K ﹤0.01% 3198

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's CRSP Position: Q2 2026 in Review

Barclays increased its CRISPR Therapeutics (CRSP) stake by 27% in Q2 2026, buying an estimated $455K and bringing the position to 40,879 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2284.

Barclays first reported a position in CRSP in Q3 2017 and has held it in 36 quarters since. The position peaked at $23.2M in Q3 2023. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Barclays held 40,879 shares of CRISPR Therapeutics worth $2.23M as of Q2 2026.
  • Barclays bought 8,625 CRISPR Therapeutics shares in Q2 2026, an estimated $455K.
  • CRISPR Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2284 holding.
  • Barclays first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 36 quarters since.
  • Barclays's CRISPR Therapeutics position peaked at $23.2M in Q3 2023.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.